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Background
The dopamine transporter (DAT) mediates dopamine
(DA) reuptake once DA gets released into the synaptic
cleft; thereby, the DAT regulates DA content available
for synaptic transmission. Psychostimulants like
amphetamines can induce the reverse operation and
induce outward transport, thereby increasing extracel-
lular dopamine concentrations. Increases of DA in the
synaptic cleft are associated with psychosis and drug
addiction. Influx and efflux of substrate via the DAT
are thought to be asymmetrical and were shown to
possess consensus sites for the regulation by intracellu-
lar kinases. It was demonstrated that the loss of N-
terminal serines ablates amphetamine-induced reverse
transport in the DAT and that Ca2+/calmodulin-depen-
dent protein kinase IIa (CaMKIIa) can physically bind
the DAT C-terminus and phosphorylate N-terminal
serines. Pharmacological inhibition of CaMKIIa with
KN93 dramatically reduces amphetamine-induced
efflux in both cells stably transfected with the human
DAT and in rat striatal slices. Here we show that
amphetamine-induced DAT-mediated efflux is reduced
in CamKIIa mutants and in a mouse model of Angel-
man syndrome (AS).
Methods
Mouse striatal synaptosomes preloaded with [3H]MPP+,
a substrate for the DAT, were superfused using a super-
fusion system. [3H]MPP+ release was induced by the
addition of 3 µM D-amphetamine. Superfusates were
collected and quantified using a szintillation counter.
Immunoblots and [3H]CFT binding experiments were
used to assess DAT protein expression levels. Uptake
assays were performed in striatal synaptosomes using
[3H]MPP+ as substrate. For non-specific uptake we used
the DAT-inhibitor mazindol.
Results
Both pharmacological inhibition of CamKIIa or genetic
ablation of CaMKIIa function (in CaMKIIa knock-out
and AS mice) reduces amphetamine-induced reverse
transport in the DAT. As CaMKIIa is one of the brain’s
most abundant proteins involved in a plethora of regula-
tory processes it is not possible to pharmacologically
target it in human AS patients. However, the DAT
would be a possible target also for these patients and it
might be promising to further investigate potential DAT
influencing medications to treat Angelman syndrome.
Conclusions
Pharmacologic inhibition of CamKIIa as well as genetic
knock-out or activity-downregulation of CamKIIa
reduce amphetamine-induced reverse transport in the
DAT.* Correspondence: harald.sitte@meduniwien.ac.at
1Institute of Pharmacology, Center of Physiology and Pharmacology, Medical
University of Vienna, 1090 Vienna, Austria
Full list of author information is available at the end of the article
Steinkellner et al. BMC Pharmacology 2010, 10(Suppl 1):A19
http://www.biomedcentral.com/1471-2210/10/S1/A19
© 2010 Sitte et al; licensee BioMed Central Ltd.
Author details
1Institute of Pharmacology, Center of Physiology and Pharmacology, Medical
University of Vienna, 1090 Vienna, Austria. 2Department of Neuroscience,
Erasmus University Medical Center, 3015 GE Rotterdam, The Netherlands.
Published: 16 November 2010
doi:10.1186/1471-2210-10-S1-A19
Cite this article as: Steinkellner et al.: Calmodulin kinase II regulates
amphetamine-induced reverse transport in the dopamine transporter:
implications for the importance of the dopamine transporter in
Angelman syndrome. BMC Pharmacology 2010 10(Suppl 1):A19.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Steinkellner et al. BMC Pharmacology 2010, 10(Suppl 1):A19
http://www.biomedcentral.com/1471-2210/10/S1/A19
Page 2 of 2
